Clostridium difficile and the microbiota
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Clostridium difficile infection (CDI) is the leading health care-associated illness. Both human and animal models have demonstrated the importance of the gut microbiota's capability of providing colonization resistance against C. difficile. Risk factors for disease development include antibiotic use, which disrupts the gut microbiota, leading to the loss of colonization resistance and subsequent CDI. Identification of the specific microbes capable of restoring this function remains elusive. Future studies directed at how microbial communities influence the metabolic environment may help elucidate the role of the microbiota in disease development. These findings will improve current biotherapeutics for patients with CDI, particularly those with recurrent disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These concepts of manipulating commensal–pathogen competition for nutrients, such as iron, may also prove relevant to C. difficile infection, where faecal microbial transfer has had therapeutic success through normalization of the commensal microbiota. 149 , 176”
From The battle for iron in enteric infections (2020) · cites this paper as [176]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 3×
“Clostridium cluster XIVa (64, 76): Proteus spp.”
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872 · cited 1×
“Various microbes have also been observed to impact subsets of T cells, such as the induction of Tregs by Clostridium species (57) and Th17 cell differentiation by segmented filamentous bacteria (58).”
BackgroundDethlefsen, L., & Relman, D. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000087107 · Cited by 2,421 · cited 1×
“Dethlefsen et al. found that although recovery began within weeks of ciprofloxacin cessation, the new community did not necessarily include all community members observed before antibiotic use (36).”
BackgroundDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“although compositional changes may be dependent on the antibiotic used as well as the underlying microbiota community of the individual (34, 35).”
BackgroundReduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277 · cited 1×
“A decreased diversity of Firmicutes and Bacteroidetes has been observed in the microbiota of IBD patients (50).”
BackgroundLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946 · cited 1×
“These increases in CDI burden have occurred in conjunction with the emergence of hyperendemic strains (4, 5).”
BackgroundComposition, variability, and temporal stability of the intestinal microbiota of the elderly
Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E., Marchesi, J. R., Falush, D., Dinan, T., Fitzgerald, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000097107 · Cited by 1,754 · cited 6×
“Using nonsequencing methods, Hopkins et al. observed that elderly patients with CDI had higher counts of Enterobacteriaceae (Proteobacteria), Enterococcus , and Lactobacillus (both Firmicutes), whereas healthy elderly patients harbored more diverse Bacteroides strains (Bacteroide-table od, fecal microbiota transplanta…”
BackgroundInfluentialThrough Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians
Biagi, E., Nylund, L., Candela, M., Ostan, R., Bucci, L., Pini, E., Nikkïla, J., Monti, D., Satokari, R., Franceschi, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010667 · Cited by 1,483 · cited 1×
“The human gut microbiome undergoes extreme changes throughout life, and it is not surprising that shifts in the microbial composition have been observed in elderly people (38, 39).”
BackgroundGaboriau-Routhiau, V., Rakotobe, S., Lécuyer, E., Mulder, I., Lan, A., Bridonneau, C., Rochet, V., Pisi, A., De Paepe, M., Brandi, G., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.020 · Cited by 1,452 · cited 1×
“Various microbes have also been observed to impact subsets of T cells, such as the induction of Tregs by Clostridium species (57) and Th17 cell differentiation by segmented filamentous bacteria (58).”
Background
Cited by
Items 101–200 of 270
Nerber, H. N., & Sorg, J. A. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009516 · Cited by 24
“difficile infections occur in individuals with a disrupted microbiota, commonly due to the use of broad-spectrum antibiotics [1,4,5].”
BackgroundInfluentialFrontiers in antibiotic alternatives for Clostridioides difficile infection
Phanchana, M., Harnvoravongchai, P., Wongkuna, S., Phetruen, T., Phothichaisri, W., Panturat, S., Pipatthana, M., Charoensutthivarakul, S., Chankhamhaengdecha, S., & Janvilisri, T. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i42.7210 · Cited by 24
Saha, A., Samadder, A., & Nandi, S. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221201150933 · Cited by 30
Kumar, R., Maynard, C. L., Eipers, P. G., Goldsmith, K. T., Ptacek, T., Grubbs, J. A., Dixon, P. B., Howard, D., Crossman, D. K., Crowley, M. R., et al. (2016) · BMC Microbiology · doi:10.1186/s12866-015-0622-2 · Cited by 27
“As evidenced from the analysis of the recipient’s microbiota, the microbe composition was very different from that of the donor with increased relative abundance of families Enterobacteriaceae, Lactobacillaceae, Enterococcaceae, consistent with a dysbiotic microbe composition [4, 25].”
BackgroundInfluentialRecent advances in the treatment of C. difficile using biotherapeutic agents
Giau, V. V., Lee, H., An, S. S. A., & Hulme, J. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s207572 · Cited by 25
Goldsmith, J. R., Tomkovich, S., Aunins, J. G., McGovern, B., Mahoney, J. C., Hasson, B. R., McChalicher, C. W. J., & Ege, D. S. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2402550 · Cited by 22
Impacts of Amino Acids on the Intestinal Defensive System
Ren, W., Bin, P., Yin, Y., & Wu, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-45328-2_8 · Cited by 21
Intestinal injury and the gut microbiota in patients with Plasmodium falciparum malaria
Sriboonvorakul, N., Chotivanich, K., Silachamroon, U., Phumratanaprapin, W., Adams, J. H., Dondorp, A. M., & Leopold, S. J. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011661 · Cited by 23
Džunková, M., Moyá, A., Vázquez-Castellanos, J. F., Artacho, A., Chen, X., Kelly, C. P., & D’Auria, G. (2016) · mSphere · doi:10.1128/msphere.00101-16 · Cited by 21
“This may be the reason for the results of metagenomics studies comparing CDI-positive and CDI-negative patients being very elusive (5, 6).”
Fecal microbiota transplantation in children: current concepts
Gurram, B., & Sue, P. K. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000787 · Cited by 23
“of broad spectrum antibiotics has been identified as the most common associated risk factor for disease [5].”
BackgroundAldriwesh, M. G., Alotibi, R. S., Alqurainy, N., Alrabiah, S., Arafah, A. M., Alghoribi, M. F., & Ajina, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2607076 · Cited by 24
“87,88 Until recently, the classical approach to therapy for C. difficile colitis was antimicrobial administration, which has a high failure rate.”
Mani, J., Levy, S., Angelova, A. G., Hazrati, S., Fassnacht, R., Subramanian, P., Richards, T., Niederhuber, J. E., Maxwell, G. L., & Hourigan, S. K. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2203969 · Cited by 23
“Contrary to previous adult studies, an increase in Enterobacteriaceae or Veilonella species was not noted with toxigenicity.(24,34,35) Since there were no distinct microbial signatures causing robust changes in diversity with carriage, it is most likely a transient component in the dynamic infant microbiome as it tran…”
ResultReturning to Nature for the Next Generation of Antimicrobial Therapeutics
MacNair, C. R., Tsai, C. N., Rutherford, S. T., & Tan, M. (2023) · Antibiotics · doi:10.3390/antibiotics12081267 · Cited by 22
van Beurden, Y. H., Nezami, S., Mulder, C. J. J., & Vandenbroucke‐Grauls, C. M. J. E. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.07.025 · Cited by 21
“It is generally assumed that the inability of the gut microbiota to re-establish colonization resistance after initial CDI adds to recurrence risk.(3,4) Alternatively, recurrent CDI may reflect failure of the host to mount a protective immune response against C.”
BackgroundHenson, M. A. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008782 · Cited by 19
“21), Gammaproteobacteria and Clostridiaceae (S10B Fig), taxa which have been reported to be elevated in CDI [73,74,78].”
BackgroundTherapeutic Approach Targeting Gut Microbiome in Gastrointestinal Infectious Diseases
Han, Z., Min, Y., Pang, K., & Wu, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115654 · Cited by 20
Lee, A. A., Rao, K. K., Limsrivilai, J., Gillilland, M. G., Malamet, B. J., Briggs, E., Young, V. B., & Higgins, P. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz335 · Cited by 21
Self-citationRNA-based control mechanisms of Clostridium difficile
Soutourina, O. A. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.01.004 · Cited by 20
The rise, fall, and resurgence of phage therapy for urinary tract infection
Zulk, J. J., Patras, K. A., & Maresso, A. W. (2024) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0029-2023 · Cited by 20
“In this way, their engineered phages, coined heterologous effector phage therapeutics (HEPTs), serve dual functions of phage-medi ated bacterial killing and production of antimicrobial compounds that are released after bacterial lysis.”
A computational method to dissect colonization resistance of the gut microbiota against pathogens
Ke, S., Xiao, Y., Weiss, S. T., Chen, X., Kelly, C. P., & Liu, Y. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100576 · Cited by 20
New insights for vaccine development against Clostridium difficile infections
Pizarro‐Guajardo, M., Chamorro-Veloso, N., Vidal, R. M., & Paredes‐Sabja, D. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.04.009 · Cited by 17
Apyrase-mediated amplification of secretory IgA promotes intestinal homeostasis
Perruzza, L., Strati, F., Raneri, M., Li, H., Gargari, G., Rezzonico-Jost, T., Palatella, M., Kwee, I., Morone, D., Seehusen, F., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111112 · Cited by 18
Heidebrecht, H.-J., Weiss, W. J., Pulse, M., Lange, A., Gisch, K., Kliem, H., Mann, S., Pfaffl, M. W., Kulozik, U., & von Eichel‐Streiber, C. (2019) · Toxins · doi:10.3390/toxins11020098 · Cited by 18
Gut Microbiota Profile and Functional Gastrointestinal Disorders in Infants: A Longitudinal Study
Pantazi, A. C., Mihai, C. M., Lupu, A., Bălașa, A. L., Chisnoiu, T., Mihai, L., Frecuș, C. E., Ungureanu, A., Chirila, S. I., Nori, W., et al. (2025) · Nutrients · doi:10.3390/nu17040701 · Cited by 17
“Clostridium difficile causes inflammation and damage to the intestinal lining, which can lead to increased mucus production [27].”
Clostridium difficile Infection: A Model for Disruption of the Gut Microbiota Equilibrium
Blanchi, J., Goret, J., & Mégraud, F. (2016) · Digestive Diseases · doi:10.1159/000443355 · Cited by 21
Protective Effect of Baicalin against Clostridioides difficile Infection in Mice
Pellissery, A. J., Vinayamohan, P. G., Kuttappan, D. A., Mishra, N., Fragomeni, B. D. O., Maas, K. R., Mooyottu, S., & Venkitanarayanan, K. (2021) · Antibiotics · doi:10.3390/antibiotics10080926 · Cited by 16
Cao, Y., Wang, L., Ke, S., Kelly, C. P., Pollock, N. R., Villafuerte-Gálvez, J., Daugherty, K., Xu, H. J., Yao, J., Chen, Y., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01362-22 · Cited by 17
Yuzuriha, K., Yakabe, K., Nagai, H., Li, S., Zendo, T., Zai, K., Kishimura, A., Hase, K., Kim, Y., Mori, T., et al. (2020) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.2020-002 · Cited by 19
“difficile colonization in the gut [31].”
Unveiling the Important Role of Gut Microbiota and Diet in Multiple Sclerosis
Džidić-Krivić, A., Begagić, E., Hadžić, S., Bećirović, A., Bečirović, E., Hibić, H., Lihić, L. T., Vukas, S. K., Bečulić, H., Kasapović, T., et al. (2025) · Brain Sciences · doi:10.3390/brainsci15030253 · Cited by 15
Wu, Q., Boonma, P., Badu, S., Yalçınkaya, N., So, S. Y., Garey, K. W., Williams, K. C., Arnold, L. E., Shulman, R. J., Kellermayer, R., et al. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00421-4 · Cited by 16
Magalhães, J., Cappellozza, B. I., dos Santos, T. C., Inoe, F., Araújo, J. P., Kurissio, J. K., Queiroz, O. C. M., Joergensen, J. N., Cooke, R. F., Vasconcelos, C. G. C., et al. (2024) · Journal of Dairy Science · doi:10.3168/jds.2023-24434 · Cited by 17
Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention
Lavoie, T., Appaneal, H. J., & LaPlante, K. L. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad639 · Cited by 17
Fatal community-acquired ribotype 002 Clostridium difficile bacteremia
Dauby, N., Libois, A., Broeck, J. V., Delmée, M., Vandenberg, O., & Martiny, D. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.12.013 · Cited by 15
Pituch, H. M., Obuch-Woszczatyński, P., Lachowicz, D., Kuthan, R., Dzierżanowska‐Fangrat, K., Mikucka, A., Jermakow, K., Pituch, A., & Davies, K. (2018) · Advances in Medical Sciences · doi:10.1016/j.advms.2018.03.003 · Cited by 14
The human microbiota and infection prevention
Araos, R., & D’Agata, E. M. C. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.28 · Cited by 17
The Human Microbiome in Health and Disease
Arnold, W., Hill, E. S., Fei, N., Yee, A. L., Garcia, M. S., Cralle, L. E., & Gilbert, J. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_39 · Cited by 15
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome
Bryant, J. A., Vulić, M., Walsh, E., Allen, E. G., Beauchemin, N., Chafee, M. E., Diao, L., Fenn, K., Ford, K. A., Hasson, B. R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04076-w · Cited by 13
“6a) 23 .”
Diarrheal disease and gut microbiome
Ramamurthy, T., Kumari, S., & Ghosh, A. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.08.002 · Cited by 18
Rooney, A. M., Cochrane, K., Fedsin, S., Yao, S., Anwer, S., Dehmiwal, S., Hota, S. S., Poutanen, S. M., Allen‐Vercoe, E., Coburn, B. A., et al. (2023) · mBio · doi:10.1128/mbio.03482-22 · Cited by 16
A contemporary review of Clostridioides difficile infections in patients with haematologic diseases
Dutta, D., Jafri, F. M., STUHR, D., Knoll, B. M., & Lim, S. H. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13173 · Cited by 15
Toward the development of defined microbial therapeutics
Li, Y., & Honda, K. (2021) · International Immunology · doi:10.1093/intimm/dxab038 · Cited by 14
Han, S., Yi, J., Kim, J., & Moon, H. (2020) · Microorganisms · doi:10.3390/microorganisms8060882 · Cited by 13
Maslanka, J. R., Gu, C. H., Zarin, I., Denny, J. E., Broadaway, S. C., Fett, B., Mattei, L. M., Walk, S. T., & Abt, M. C. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1851999 · Cited by 13
“difficile to grow.(4,5) Upon establishment of infection, C.”
BackgroundMicrobiome therapeutics for the treatment of recurrent Clostridioides difficile infection
Bloom, P. P., & Young, V. B. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2154600 · Cited by 12
Self-citationNerber, H. N., Baloh, M., Brehm, J. N., & Sorg, J. A. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012507 · Cited by 12
“difficile produces endospores that are shed into the environment, can withstand oxygen and other environmental insults, and serve as the transmissive form of the organism [5-7].”
BackgroundMallia, G., Toen, J. V., Rousseau, J., Jacob, L., Boerlin, P., Greer, A., Metcalf, D. S., & Weese, J. S. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.01.020 · Cited by 12
Metabolic Modeling of Clostridium difficile Associated Dysbiosis of the Gut Microbiota
Phalak, P., & Henson, M. A. (2019) · Processes · doi:10.3390/pr7020097 · Cited by 12
Human Plasminogen Exacerbates Clostridioides difficile Enteric Disease and Alters the Spore Surface
Awad, M. M., Hutton, M. L., Quek, A. J. H., Klare, W. P., Mileto, S. J., Mackin, K. E., Ly, D., Oorschot, V. M. J., Bosnjak, M., Jenkin, G., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.032 · Cited by 12
De novo design of potent inhibitors of clostridial family toxins
Ragotte, R. J., Liang, H., Tam, J., Miletic, S., Berman, J. M., Palou, R., Weidle, C., Li, Z., Glögl, M., Beilhartz, G. L., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2509329122 · Cited by 13
Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile
Abouelkhair, A. A., & Seleem, M. N. (2024) · mSphere · doi:10.1128/msphere.00273-24 · Cited by 11
“Spore germination and toxin production will transpire if the metabolic and microbiolog ical environment of the gut has been disturbed (15, 16).”
BackgroundMorales, L., Rodríguez, C., & Gamboa-Coronado, M. D. M. (2016) · American Journal of Infection Control · doi:10.1016/j.ajic.2016.09.003 · Cited by 11
Jeon, Y. D., Ann, H. W., Lee, W. J., Kim, J. H., Seong, H., Kim, J. H., Ahn, J. Y., Jeong, S. J., Ku, N. S., Yeom, J., et al. (2019) · Infection and Chemotherapy · doi:10.3947/ic.2019.51.4.365 · Cited by 12
“Clostridioides difficile infection (CDI) is a major focus of research in the study of gut microbiota [9].”
BackgroundHost origin of microbiota drives functional recovery and Clostridioides difficile clearance in mice
Millard, S., Vendrov, K. C., Young, V. B., & Seekatz, A. M. (2025) · mBio · doi:10.1128/mbio.01108-25 · Cited by 11
“A diverse gut microbiota typically helps prevent initial colonization and disease if an individual encounters C. difficile spores from the environment (2, 3).”
Self-citationCitrulline Inhibits Clostridioides difficile Infection With Anti-inflammatory Effects
Xie, Y., Irwin, S. L., Nelson, B., van Daelen, M., Fontenot, L., Jacobs, J. P., Cappelletti, M., Feng, H., Li, Y., & Koon, H. W. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101474 · Cited by 11
The Microbiome and the Epigenetics of Diabetes Mellitus
Dávila, L. A., Bermúdez, V., Díaz, W., Villasmil, N. R., Cisternas, S., Contreras, M. C. E., Kristian Buhring, B., Durán‐Agüero, S., Vergara, P. C., Bonacich, R. B., et al. (2018) · InTech eBooks · doi:10.5772/intechopen.76201 · Cited by 13
“Gut microbiota transplants can help to increase the richness and diversity of GM [76].”
BackgroundJouhten, H., Ronkainen, A., Aakko, J., Salminen, S., Mattila, E. J., Arkkila, P., & Satokari, R. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01663 · Cited by 10
“composition when compared to healthy individuals (Chang et al., 2008; Seekatz and Young, 2014).”
Rizzo, K. R., Yi, S. H., Garcia, E. P., Zahn, M., & Epson, E. E. (2019) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2019.135 · Cited by 10
“The main effect estimates of interest for the 3 groups consisted of (1) the baseline rate trend; (2) the level change in rate immediately following collaborative implementation in September 2015; (3) the change in rate trend between the baseline and follow-up periods; and (4) the follow-up rate trend.”
BackgroundTeicoplanin Suppresses Vegetative Clostridioides difficile and Spore Outgrowth
Ojha, S. C., Phanchana, M., Harnvoravongchai, P., Chankhamhaengdecha, S., Singhakaew, S., Ounjai, P., & Janvilisri, T. (2021) · Antibiotics · doi:10.3390/antibiotics10080984 · Cited by 10
Kester, J. C., Brubaker, D. K., Velazquez, J. G., Wright, C. W., Lauffenburger, D. A., & Griffith, L. G. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01404-19 · Cited by 9
“Increased relative abundance of proteobacteria is associated with CDAD and has been proposed to be a risk factor (54).”
BackgroundGolchha, N. C., Nighojkar, A., & Nighojkar, S. (2022) · Drug Target Insights · doi:10.33393/dti.2022.2469 · Cited by 11
“CDI is usually followed by the antibiotic treatment that impairs the protective gut microflora (8).”
BackgroundMicrobiota Talks Cholera out of the Gut
Hay, A. J., & Zhu, J. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.10.011 · Cited by 8
“Infection can be blocked by colonization with nonpathogenic strains and can be cured via transplantation of a healthy microbial community (Seekatz and Young, 2014).”
BackgroundThe human gut microbiome in enteric infections: from association to translation
Yin, Q., Gupta, S., Muller, E., & Almeida, A. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2612836 · Cited by 8
“16 However, the precise mechanisms and gut commensal species behind C. difficile colonization resistance are still unclear.”
Chen, P.-C., Lin, M., Lin, T.-C., Kang, T.-W., & Ruan, J. (2023) · Bioinformatics and Biology Insights · doi:10.1177/11779322231166229 · Cited by 8
“13 However, no clear feature of gut microbiota changes has been suggested to be sufficient for concurrently monitoring dysbiosis during the antibiotic treatment period.”
BackgroundMartín‐Loeches, I., Léone, M., & Einav, S. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05870-0 · Cited by 7
Louie, T. J., Ribble, W., Boccumini, L., Johnson, K., Groote, M. A. D., Day, J. J., Mason, C., Sun, X., Freeman, J., Gu, K., et al. (2026) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00721-2 · Cited by 6
“Persistent disruption of normal microbiota during treatment of CDI is a driving factor in the recurrence of CDI, 5,6 which remains a major clinical challenge with the currently available treatment options.”
Zermeño-Ruiz, M., Gutiérrez-Gutiérrez, F., Anaya-Ambriz, E. J., Peña-Durán, E., García-Galindo, J. J., Huerta-Huerta, A., Quiñonez-Gallardo, A. L., & Suárez-Rico, D. O. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031610 · Cited by 8
“In parallel, there is an increase in pathogenic taxa such as Enterococcus , Escherichia , and other Proteobacteria , which exacerbate inflammation and the production of toxic metabolites [65,66].”
Sehgal, K., & Feuerstadt, P. (2024) · Frontiers in Microbiomes · doi:10.3389/frmbi.2024.1399440 · Cited by 9
Tian, J., Liu, H., Guo, H., Han, W., Ding, H. J., & Chen, T. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9488 · Cited by 8
“Antibiotics can definitely decrease the morbidity and mortality rates of infectious diseases (2).”
BackgroundYan, D., Huang, Y., Chen, Y., Lv, T., Zhu, C., Huang, J., & Li, L. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.03.004 · Cited by 6
Dahiya, M., Jovel, J., Monaghan, T. M., Wong, K., Elhenawy, W., Chui, L., McAlister, F. A., & Kao, D. H. (2023) · Microorganisms · doi:10.3390/microorganisms11041078 · Cited by 6
“In CDI patients and asymptomatic carriers, microbial richness is reduced in comparison with healthy individuals [10,11].”
BackgroundExtraintestinal Manifestations of Clostridioides difficile Infections: An Overview
Mpakogiannis, K. C., Fousekis, F. S., Elemes, S., Mantellos, E., Christaki, E., & Katsanos, K. H. (2025) · Antibiotics · doi:10.3390/antibiotics14070670 · Cited by 5
Deciphering the Structural and Functional Paradigms of Clostridioides difficile Toxins TcdA and TcdB
Qutub, M., Tatode, A., Hussain, U., Premchandani, T., Taksande, J., Umekar, M. J., & Thakre, D. (2025) · Bacteria · doi:10.3390/bacteria4020021 · Cited by 7
“Recent studies have highlighted specific bacterial taxa, metabolic pathways, and immune interactions that contribute to microbiota-mediated resistance against C. difficile [90].”
D’Agata, E. M. C., Apata, I. W., Booth, S., Boyce, J. M., Deaver, K. D., Gualandi, N. R., Neu, A. M., Nguyen, D. B., Novosad, S., Palevsky, P. M., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.02.028 · Cited by 5
Bacterial Fecal Microbiota in Healthy Subjects and Inpatients with Clostridium difficile Infection
Barbosa, T. F., Secco, D., Peixoto, R. S., Rosado, A. S., do Carmo, F. L., de Jesus, H. E., Lobo, L. A., Antunes, L. C. M., Miranda, K. R., de Paula, G. R., et al. (2017) · Advances in Microbiology · doi:10.4236/aim.2017.71002 · Cited by 5
“, together with members of the Clostridiales order, was basically found dominating the healthy gut microbiota [18].”
BackgroundZhang, C., Virk, A. K., KHAN, I. A., & Qin, H. (2020) · Springer eBooks · doi:10.1007/978-981-15-4759-1_2 · Cited by 5
Dey, P., & Moludi, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85730-7.00030-8 · Cited by 5
Young, V. B. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00341.2016 · Cited by 4
“difficile spores, these can germinate and establish residence in the gastrointestinal tract with subsequent development of clinically overt CDI (39).”
BackgroundSelf-citationSeekatz, A. M., & Young, V. B. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.036 · Cited by 4
Self-citationKato, H., Hagihara, M., Shiraishi, C., Asai, Y., Mikamo, H., & Iwamoto, T. (2025) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2025.104979 · Cited by 3
Yousefi, F., Sponseller, B., Muyyarikkandy, M. S., Praveen, N., Greene, M. W., & Mooyottu, S. (2025) · npj gut and liver. · doi:10.1038/s44355-024-00016-6 · Cited by 3
Guo, Y., Zhang, Y., Wang, G., Liu, H., Wang, J., Deng, X., He, L., & Qiu, J. (2024) · eLife · doi:10.7554/elife.101757.4 · Cited by 4
Mons, E., Henderickx, J. G. E., Sanders, I. M. J. G., Rader, A. G., Perkins, C. E., Stel, F. M., van Groesen, E., Smits, W. K., Theriot, C. M., & Martin, N. I. (2025) · Nature Communications · doi:10.1038/s41467-025-64067-w · Cited by 3
Bernabé, G., Castagliuolo, I., Porzionato, A., Casarotto, G., Monte, R. D., Carpi, A., & Brun, P. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127812 · Cited by 3
Impact of type 2 diabetes mellitus on mortality and recurrence of clostridioides difficile infection
Martinez-Cuevas, C., Nájera, M., Otero, J. A., Martín, M. G., de Frutos, M., Bouza, J. M. E., Corral-Gudino, L., & Miramontes‐González, J. P. (2024) · Hospital Practice · doi:10.1080/21548331.2024.2440305 · Cited by 3
“On the other hand, the alteration of the microbiota is one of the bases of the etiopathogeny of clostridioides infection, in addition to being a therapeutic option, microbiota transplantation in recurrent disease [19].”
Kamath, S., & Skariyachan, S. (2017) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-017-0215-x · Cited by 3
“difficile is capable of causing diseases such as pseudo membranous colitis (PC) [7].”
BackgroundLiu, L., Zhou, X., Li, B., Cheng, F., Cui, H., Li, J., & Zhang, J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00581-21 · Cited by 2
“difficile from the environment (29), or failure to reestablish the normal gut microflora (30, 31).”
BackgroundExpansion of a versatile pathogen: Clostridioides difficile
Lucas, T., & Brown, B. (2024) · Hygiene and Environmental Health Advances · doi:10.1016/j.heha.2024.100108 · Cited by 3
Enhancing Survival Following High-Risk Surgery by Modulating Actionable Items within the Pathobiome
Zaborina, O. Y., Zaborin, A., Keskey, R. C., & Alverdy, J. C. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010335 · Cited by 2
Adamowicz, E. M., Kraft, C. S., Ward, T., Mehta, N., Shannon, W. D., Mishra, R., & Blount, K. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf382 · Cited by 2
“Disruption of the microbiome composition and diversity can impair these functions and allow for colonization and/or infection by opportunistic pathogens such as Clostridioides difficile [1, 3, 4], Enterobacterales [5], and enterococci [6], among others.”
Bălaș‐Maftei, B., Florea, C.-E., Adudanii, P. L., Stoian, I. A., Costin, C. A., Grigoriu, M. G., Irimie-Băluţă, E., Sandu, O.-M., Rotaru, A., & Manciuc, C. D. (2026) · Medicina · doi:10.3390/medicina62071311 · Cited by 2
“Hospital-onset/healthcare-facility-associated CDI 5.31 cases/1000 admissions 5.00 cases/10,000 patient-days Global (59 studies) [1] Long-term care facilities 44.24 cases/10,000 patient-days Global [1] Europe (HA-CDI) 2.58 cases/10,000 patient-days EU/EEA [14] https://doi.org/10.3390/medicina62071311”
InfluentialImmunosenescence and infectious diseases
Moutschen, M. P., Martens, H., & Geenen, V. G. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198701590.003.0079 · Cited by 2
La microbiota intestinal en el paciente crítico
Buendía, E., Sánchez, M., Cruz-Maldonado, O. A., & Castell, C. R. D. (2018) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2018.06.010 · Cited by 3
Gut microbiota: its development and relation to certain diseases
Sepová, H. K., Dudík, B., & Bilková, A. (2017) · Česká a slovenská farmacie · doi:10.36290/csf.2017.038 · Cited by 3
Methods in Computational Biology
Carlson, R. P., & Sauro, H. M. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-164-7 · Cited by 2
Najarian, A. (2017) · The Atrium (University of Guelph) · Cited by 3
Oliveira, P. H., Ribis, J. W., Garrett, E. M., Trzilova, D., Kim, A., Sekulović, O., Mead, E. A., Pak, T., Zhu, S., Deikus, G. Y., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/398891 · Cited by 2
“upstream of the pathogenicity locus (PaLoc) (position 786,216), in prophage genes (1,593,616), within the atp operon (3,430,190), and in the xylose operon (3,561,672) (Supplementary Fig.”
BackgroundAgrawal, G. K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06291-6 · Cited by 2
Graham, M., DiBenedetto, N., Delaney, M. L., Lavin, R., Pavao, A., Yeliseyev, V., & Bry, L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.12.495821 · Cited by 2
McDonnell, K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062040 · Cited by 2
Novacescu, D., Cut, T. G., Băloi, A., Herlo, A., Luput-Andrica, I.-M., Saizu, A.-E., Uzum, A., Mot, M. D., Zară, F., Săndesc, D., et al. (2026) · Diseases · doi:10.3390/diseases14020077 · Cited by 1
“Several studies have reported that probiotic formulations containing Bifidobacterium and Lactobacillus species may reduce ADD and, in selected contexts, CDI recurrence, when used adjunctively to standard therapy [11,27].”
Metadata
- Authors
- Seekatz, A. M., & Young, V. B.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Young, Vincent B.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-07-18
- Volume
- 124
- Issue
- 10
- Pages
- 4182-4189
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4191019
- OpenAlex
- W2020298266
- Cited by
- 255
- References
- 100
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 15 · 2023: 16 · 2022: 22 · 2021: 17 · 2020: 31 · 2019: 23 · 2018: 28 · 2017: 28 · 2016: 19 · 2015: 13 · 2014: 4
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Michigan (48109)
- National Institutes of Health
- College of Pharmacy, University of Michigan
- Medical School, University of Michigan
- National Institute of Allergy and Infectious Diseases (U19AI090871)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Clostridium difficile infection, gut microbiota, colonization resistance, antibiotic-induced dysbiosis, recurrent Clostridium difficile infection, biologic therapy, nosocomial infections
- MeSH terms
- Age Factors, Aged, Animals, Clostridium Infections, Humans, Immune System, Recurrence, Risk Factors, Spores, Bacterial, Clostridioides difficile, Gastrointestinal Tract, Mice, Microbiota, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.